Physiome Licenses PathwayPrism Technology to 3rd Millennium | GenomeWeb

NEW YORK, Aug. 28 – Physiome Sciences has licensed its PathwayPrism modeling technology to 3rd Millennium to help it develop products for Huntington’s disease, the companies said on Tuesday.

The deal will allow Cambridge, Mass.-based 3rd Millennium and its academic partners “to visualize and stimulate pathways” involved in the disease, the companies said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.